Table 3.
Treatment interaction with radiomics signature (RS) for DFS in patients with gastric cancer.
| RS | CT | No CT | Disease-free Survival | ||
|---|---|---|---|---|---|
| CT vs No CT, | P | P value for | |||
| HR (95% CI) | interaction | ||||
| Stage II (n = 269) | |||||
| RS high | 38 | 53 | 0.537(0.333–0.865) | 0.011 | 0.030 |
| RS-SVM low | 95 | 83 | 2.194(0.695–6.920) | 0.18 | |
| Stage III (n = 470) | |||||
| RS high | 59 | 77 | 0.469(0.360–0.612) | <0.001 | 0.001 |
| RS-SVM low | 167 | 167 | 1.145(0.823–2.568) | 0.198 | |
| Stage II+III (n = 739) | |||||
| RS high | 97 | 130 | 0.411(0.247–0.686) | 0.001 | <0.0001 |
| RS low | 262 | 250 | 1.562(0.941–2.594) | 0.085 | |
CT, chemotherapy; DFS, disease-free survival.